



Cancer Molecular Biology and Drug Discovery

Guest Editor:

Dr. Pei-Ming Yang

Graduate Institute of Cancer
Biology and Drug Discovery,
College of Medical Science and
Technology, Taipei Medical
University, Taipei 11031, Taiwan

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

Dear Colleagues,

Cancer is a major health issue worldwide, with an increasing global burden in the coming years. Some malignancies, such as colorectal, breast, prostate, and pancreatic cancers, are still incurable in advanced stages. Thus, more effective anticancer drugs are always urgently needed. The process of drug discovery is still risky, lengthy, and costly, and only a few new anticancer drugs have received approval in recent years. Drug repurposing is an unconventional drug discovery approach to explore new disease indications from existing clinical drugs. Exploring polypharmacology is highly useful for discovering drugs' novel MOAs to improve their therapeutic efficacies and treat different diseases. The advantages of drug repurposing include a reduction in cost and the bypass of safety concerns because extensive drug data are often available.

This Special Issue will focus on the development of novel cancer therapy based on polypharmacology and drug repurposing strategies. We welcome original research articles and review articles in this field.





Editor-in-Chief

Prof. Dr. Yehia Mechref

Department of Chemistry and
Biochemistry, Texas Tech
University, Lubbock, TX 79409,
USA

Message from the Editor-in-Chief

BioChem is an international and interdisciplinary open access journal encompassing the fields of molecular biology, cell biology, structural biology, nucleic acid biology, chemical biology, synthetic biology, disease biology, biophysics, and theoretical biochemistry. It publishes reviews, research articles, communications, and letters. Our aim is to encourage scientists to publish their experimental and theoretical research in as much detail as possible.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 54 days after submission; acceptance to publication is undertaken in 16.5 days (median values for papers published in this journal in the second half of 2023).

Recognition of Reviewers: APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.

Contact Us

BioChem Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biochem
biochem@mdpi.com
[X@BioChem_MDPI](https://twitter.com/BioChem_MDPI)